Association between spironolactone use and COVID-19 outcomes in population-scale claims data: a retrospective cohort study.
Henry C CousinsRuss B AltmanPublished in: medRxiv : the preprint server for health sciences (2023)
Spironolactone use was associated with a protective effect against ventilation and mortality following COVID-19 infection, amounting to up to 64% of the protective effect of vaccination against ventilation and consistent with an androgen-dependent mechanism. The findings warrant initiation of large-scale randomized controlled trials to establish a potential therapeutic role for spironolactone in COVID-19 patients.
Keyphrases
- sars cov
- coronavirus disease
- randomized controlled trial
- respiratory failure
- mechanical ventilation
- health insurance
- electronic health record
- cardiovascular events
- risk factors
- big data
- respiratory syndrome coronavirus
- systematic review
- cardiovascular disease
- type diabetes
- clinical trial
- artificial intelligence
- insulin resistance
- data analysis